This led to an impairment (92% for goodwill) on the former Rhodia and Chemlogics activities (Novecare – Advance Formulations), which damaged the Q3 figures and came fully out of the blue. In Solvay’s ‘adjusted world’, the impairment does not play a role and these figures look quite nice and are therefore completely misleading. Due to the impairment, the figures did not meet our expectations, but otherwise they would have been broadly in line. As consensus is mainly bas
07 Nov 2019
Weaker expectations for the oil & gas business
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Weaker expectations for the oil & gas business
Solvay SA (SOLB:WBO) | 0 0 0.5% | Mkt Cap: 11,953m
- Published:
07 Nov 2019 -
Author:
Martin Schnee -
Pages:
3
This led to an impairment (92% for goodwill) on the former Rhodia and Chemlogics activities (Novecare – Advance Formulations), which damaged the Q3 figures and came fully out of the blue. In Solvay’s ‘adjusted world’, the impairment does not play a role and these figures look quite nice and are therefore completely misleading. Due to the impairment, the figures did not meet our expectations, but otherwise they would have been broadly in line. As consensus is mainly bas